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Time to progression of mantle cell lymphoma after high-dose
cytarabine-based regimens defines patients risk for death
The current standard treatment of younger patients with
mantle cell lymphoma (MCL) includes rituximab and high-
dose cytarabine (HD-AraC), usually followed by autologous
stem cell transplantation (ASCT). This approach has
improved the long-term outcome of these patients. However,
no plateau in survival curves has been observed, and virtually
all patients will experience disease recurrence for which no
standard therapy exists (Dreyling et al, 2017). Allogeneic
stem cell transplantation (AlloSCT) remains the only option
with curative potential (Robinson et al, 2015; Tessoulin et al,
2016; Rule et al, 2017).
The data included in the largest report on MCL patients
who relapsed after ASCT was obtained between 2000 and
2009, but only 50% of cases had documented exposure to
rituximab and HD-AraC before ASCT (Dietrich et al, 2014).
Inclusion criteria for this retrospective study of first-
relapsed or -refractory MCL patients from 26 centres associ-
ated to the Fondazione Italiana Linfomi (FIL) were: (i)
upfront treatment with intensive regimens including ritux-
imab and HD-AraC, defined as cytarabine with a single dose
>1 g/m2; (ii) MCL diagnosed between 1 January 2007 and 31
June 2016. Upfront regimens were stratified into three cate-
gories: high dose sequential therapy followed by ASCT
(Geisler et al, 2008; Magni et al, 2009); R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisolone)
alternating with R-DHAP (rituximab, dexamethasone,
HD-AraC, cisplatin) followed by ASCT (Hermine et al,
2016); R-HyperCVAD/MTXHDAC (rituximab, hyperfrac-
tionated cyclophosphamide, vincristine, doxorubicin, dexam-
ethasone, high-dose methotrexate/cytarabine) followed by
Table I. Clinical and pathological characteristics of 188 relapsed or refractory patients with MCL, classified by time to disease relapse or progres-







n = 98 P value
MCL Younger Validation Set
n = 93
Median Age, years (range) 57 (35–68) 58 (35–67) 57 (35–68) 095 56 (33–65)
<60 years 117 (62%) 56 (62%) 61 (62%) 099 63 (68%)
Gender: Male 143 (76%) 67 (74%) 76 (77%) 061 78 (84%)
Stage: IV 168 (89%) 81 (90%) 87 (89%) 089 78 (84%)
B symptoms: Yes 61 (32%) 39 (43%) 22 (22%) 0002 40 (43%)
Bone marrow biopsy: Positive 155/183 (85%) 76/87 (87%) 79/96 (82%) 034 75 (81%)
MIPI score
Low 63 (34%) 24 (27%) 39 (40%) 013 46 (49%)
Intermediate 56 (30%) 28 (31%) 28 (28%) 27 (29%)
High 69 (37%) 38 (42%) 31 (32%) 20 (22%)
Ki-67 expression: ≥30% 73/141 (52%) 51/72 (71%) 22/69 (32%) 00001 16/44 (36%)
Morphological variants
Classical 134/171 (79%) 54/79 (68%) 80/92 (87%) 001 51/58 (88%)
Pleomorphic 9/171 (5%) 6/79 (7%) 3/92 (3%) 3/58 (5%)
Blastoid 28/171 (16%) 19/79 (24%) 9/92 (10%) 4/58 (7%)
Induction therapy
HyperCVAD/MTXHDAC 49 (26%) 21 (23%) 28 (29%) 051 0 (0%)
R-CHOP/DHAP + ASCT 40 (21%) 22 (25%) 18 (18%) 93 (100%)
Nordic/R-HDS 99 (53%) 47 (52%) 52 (53%) 0 (0%)
Bold indicates significant values.
Mann–Whitney test was adopted for comparing continuous variables; Chi-square test was used for nominal variables.
MIPI high versus others P = 013; Blastoids versus others P = 001.
ASCT, autologous stem cell transplantation; R-hyperCVAD/MTXHDAC, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin,
dexamethasone, high-dose methotrexate/cytarabine; MCL, mantle cell lymphoma; MIPI, Mantle cell lymphoma International Prognostic Index;
POD, progression of disease; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-DHAP, rituximab, dexametha-
sone, high-dose cytarabine, cisplatin.
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ASCT at the discretion of the treatment physician (Roma-
guera et al, 2010).
Progression of disease (POD) included primary refractory
disease, defined as no response or progression during front-
line therapy, and relapsed MCL, defined as relapse after
achieving partial or complete remission at the end of induc-
tion therapy. Primary outcome was overall survival from
POD (OS-2), defined as time from POD until death due to
any cause. The European MCL Network randomized, phase
3, MCL Younger trial (Hermine et al, 2016) was used for
independent validation of our findings (Data S1).
We modelled the relationship between time to POD
(TTP) and risk of death using a restricted cubic splines
transformation in a Cox proportional hazards model. The
curve slope (Fig 1A) showed an approximately linear associa-
tion within 24 months from MCL diagnosis, while it became
flat thereafter, with a point of inflection located around
24 months. Based on this trend, patients were grouped as
POD within 24 months of lymphoma diagnosis (early POD
group), and those with POD after 24 months of lymphoma
diagnosis (late POD group). The 24-month cut-off point
approximated the median TTP of recruited patients
(25 months, range 2–104). Of the 188 evaluable patients, 90
(48%) had early POD and 98 (52%) had late POD. Patient
characteristics are noted in Table I.
Median follow-up time from POD was 30 months (range
3–100), and median OS-2 was 34 months (95% confidence
interval [CI], 22–49, Fig 1B). Median OS-2 in the early POD
group was 12 months (95% CI, 5–17), while it was not
reached for late POD patients (5-year OS-2 55%, 95% CI,
46–62, Fig 1C, logrank P < 00001). Multivariable Cox
regression analysis associated early POD with markedly
reduced OS-2, with a hazard ratio (HR) of 390 (95% CI,
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Fig 1. (A) Analysis of 188 patients with mantle cell lymphoma experiencing first relapse or progression of disease (POD). Hazard model showing
the relationship between risk of death (Log relative hazard) and time to first relapse or progression (TTP). The vertical dotted line is allocated at
the 24 months cut-off. (B) Overall survival from time of POD (OS-2) for all 188 included patients. (C) OS-2 according to POD (early POD
versus late POD, P < 00001). (D) OS-2 in 41 patients that received allogeneic stem cell transplantation (AlloSCT) at any time during study
follow-up. Patients with late POD that had AlloSCT (n = 23) had similar OS-2 compared to patients with early POD receiving AlloSCT (n = 18,
P = 072). [Colour figure can be viewed at wileyonlinelibrary.com]
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an elevated risk of death after adjustment for MCL Interna-
tional Prognostic Index (MIPI) score, Ki-67 expression,
combined MIPI, morphological variants and presence of
B-symptoms. Subgroup analyses of patients receiving differ-
ent initial therapy demonstrated similar patterns in the peak
hazard of death. Patients refractory to induction therapy
(n = 24) had a similar OS-2 (median 64 months) to respon-
sive patients that relapsed within 12 months (n = 15; median
79 months; P = 052). The OS-2 curve and the multivariate
analysis results for the 188 patients grouped according to
TTP with different cut-offs (0–12, 12–24, >24 months), and
the HR associated to different cut-offs (HR of 829, 239, 1,
respectively) are reported in Fig S1.
Forty-one patients (22%) underwent AlloSCT, of whom 28
(68%) were transplanted in second remission and 13 (32%)
in third remission or later. AlloSCT had a favourable signifi-
cant impact on survival (HR = 045, 95% CI: 024–084;
P = 0012), and a significant effect modification of AlloSCT
according to POD time was detected (Pinteraction = 0012).
When we censored patients receiving AlloSCT at the time of
transplant in an exploratory analysis, early POD was still the
strongest independent variable associated with shorter OS-2
(HR = 398, 95% CI: 205–741; P < 00001, Data S2,
Table SI). The 18 early POD patients that received AlloSCT,
either in second (n = 10) or later (n = 8) remission, had sim-
ilar OS-2 to patients with late POD that received AlloSCT
(HR = 081, 95% CI: 025–256, P = 072, Fig 1D).
For the 93 patients in the validation set, median OS-2 was
10 months (95% CI, 6–13). Results from the Cox model con-
firmed that patients with early POD had an increased risk of
death (HR 283; 95% CI, 166–482, P = 00001, Data S1,
Table SII and SIII). Median OS-2 of the patients with late
POD was shorter in the validation cohort than the FIL series
(33 months; 95% CI, 13–55, Fig S2), which may reflect the
more frequent use of recently developed second line therapies
in the FIL series (i.e. ibrutinib or bendamustine-based combi-
nations, such as R-BAC [rituximab, bendamustine, cytara-
bine] in 69% of patients), as compared to the validation set.
Overall, there is a clear need to identify biological subsets
that can be defined prospectively along with associated
expected outcomes, such as TP53 mutations or aberrations
(Eskelund et al, 2017), which were not investigated in the
present study. Given that the expected median survival for
younger patients with MCL exceeds 10 years, POD within
2 years of diagnosis identifies a population of patients who
have remarkably poor outcomes, irrespective of the prognos-
tic information obtained at diagnosis or induction regimen
administered. This newly defined high-risk group of patients
represents a distinct population in whom further study is
warranted in both directed prospective clinical trials of MCL
biology and treatment, including AlloSCT. Likewise, the
observation that patients with relapse beyond 2 years have
prolonged survival expectation in the modern treatment era
seems of great importance in the clinical management of
patients with MCL.
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Fig S1. (A) OS-2 curve for the 188 patients divided
according to TTP with different cut-offs (0–12, 12–24,
>24 months); (B) Cox Model for OS-2 according to TTP
with different cut-offs.
Fig S2. (A) Overall survival from time of POD (OS-2) for
the 93 patients of the validation set (HDAraC group of the
MCL Younger trial). (B) OS-2 according to time to POD
(early POD versus late POD, P < 0.0001) in the validation
set.
Data S1. Validation of the prognostic effect of time to
first treatment failure in mantle cell lymphoma patients
refractory to or relapsing after high-dose-cytarabine-contain-
ing treatment.
Data S2. List of regimens used as second line treatment.
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